In regards to my estimate, since there is no new data, I have revised my starts to about 115 thru April 30. This is based on the following assumptions:
1) Linear ramp based on starts thru Feb (approximately 1.55 patient starts per ATC per month) for the 30 existing ATCs (assuming no adds from the 6 additional ATCs thru April)
2) Fred's comments upon approval and re-iteration during Cowen fireside that the 20 patients were "a tiny fraction of the bolus".
3) Build of of the iCTC for a capacity of 2,000 (165/month) plus a vendor back up because they did not want to end up in a situation similar to the CAR-T roll out where initial demand outstripped capacity.
4) ATCs investment in time and resources (200 hours for the lead physician + support staff training plus infrastructure) is a big commitment from the Cancer Centers so they would expect some demand before committing to becoming an ATC.
The Q2 analyst revenue projections are 5.2M (low), $28.6M (average) and $60.6M (high). This equates to about 10, 58 and 122 starts thru April. We are already way over the 10 thru Feb and only an additional 38 to get to the average. I am confident that we will blow away those 2 and should be closer to the top-end. I was playing that expected pop using some options, but this continued weakness may not hit those strikes even with a substantial beat.
This weakness continues to surprise me. I will probably add some additional lower strike options right before earnings if this weakness/lower level continues.
Recent IOVA News
- Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma • GlobeNewswire Inc. • 06/28/2024 11:00:00 AM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 06/21/2024 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 10:03:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 10:00:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 09:15:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 12:07:04 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 12:05:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 12:04:19 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 12:01:02 PM
- Iovance Biotherapeutics to Present at Upcoming Conferences and Events • GlobeNewswire Inc. • 05/24/2024 08:01:00 PM
- Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting • GlobeNewswire Inc. • 05/23/2024 09:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/17/2024 09:15:06 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/17/2024 09:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 09:10:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:06:00 PM
- Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates • GlobeNewswire Inc. • 05/09/2024 08:01:00 PM
- Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024 • GlobeNewswire Inc. • 05/01/2024 10:01:00 AM
- Iovance Biotherapeutics to Present at Upcoming Conferences • GlobeNewswire Inc. • 04/30/2024 10:01:00 AM
- Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 04/24/2024 08:01:00 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/19/2024 09:15:00 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/22/2024 09:30:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 10:56:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 10:53:27 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM